Pharmacognosy, Phytochemistry & Natural Products

Biography

Biography: Aderogba M A

Abstract

Tuberculosis is currently one of the most serious bacteria infectious diseases worldwide. There is need for development of new therapy due to emergence of resistant tuberculosis strains, to first line antibiotics known as single-drug resistant, Multi-Drug Resistant (MDR) and Extensive-Drug Resistant (XDR). Several reports have documented antimycobacterial properties of many Terminalia species but only a few species have been explored for their antimycobacterial constituents. This paper presents activity directed fractionation of a 80% methanol crude extracts of Terminalia phanerophlebia leaves leading to the isolation of compounds responsible for its antimicrobial activities. T. phanerophlebia crude extracts was in turned extracted with solvents of varying polarities: hexane, dichloromethane (DCM), ethyl acetate (EtOAc) and n-butanol. The solvent and column fractions obtained along with the isolated compounds were tested for antibacterial activities against Mycobacterium aurum A+, Mycobacterium tuberculosis H37Ra, Staphylococcus aureus and Klebsiella pneumoniae. Of all the solvent fractions tested, EtOAc fraction exhibited highest antimicrobial activities and its bioguided fractionation afforded methyl gallate (1) and a phenylpropanoid glucoside, 1,6-di-O-coumaroyl glucopyranoside (2). Isolated compounds(1) and (2) are reported from T. phanerophlebia for the first time, and they demonstrated good antimicrobial activity against all bacterial strains tested with minimum inhibitory concentration (MIC) values ranging from 63 to 250 µg/mL. In this study, 1,6-di-O-coumaroyl glucopyranoside (2) significantly inhibited Mycobacterium tuberculosis (MIC = 63 µg/mL) a leading cause of tuberculosis worldwide. Antimicrobial activities exhibited by the extracts and isolated compounds from Terminalia phanerophlebia confirm the traditional use of this plant in treating tuberculosis and its related symptoms.